Zuventus has always been at the forefront in bringing innovation and excellence in Healthcare.

As part of this commitment to the medical fraternity & patients, Zuventus introduced a novel concept-based molecule, Trelagliptin (Trelaglip), a Once-Weekly Oral DPP4i for the management of Type 2 Diabetes Mellitus (T2DM), designed to address existing challenges in glycemic control & patient compliance.

Trelaglip makes a difference to QoL with Compliance & Control, available in 3 SKUs (100 MG, 50 MG & 25 MG) 

• For the first time in India, Zuventus conducted a clinical trial comparing Trelagliptin 100 MG (once-weekly) vs. Vildagliptin 50 MG BID & got CDSCO approval.

Zuventus has always been at the forefront in bringing innovation and excellence in Healthcare.

As part of this commitment to the medical fraternity & patients, Zuventus introduced a novel concept-based molecule, Trelagliptin (Trelaglip), a Once-Weekly Oral DPP4i for the management of Type 2 Diabetes Mellitus (T2DM), designed to address existing challenges in glycemic control & patient compliance.

Trelaglip makes a difference to QoL with Compliance & Control, available in 3 SKUs (100 MG, 50 MG & 25 MG) 

• For the first time in India, Zuventus conducted a clinical trial comparing Trelagliptin 100 MG (once-weekly) vs. Vildagliptin 50 MG BID & got CDSCO approval.

Composition: Each Sachet contains: Not less than 30.0 billion CFU of Bifidobacteria (B. Longum DSM 24736, B. Breve DSM 24372, B. Infantis DSM 24737), Streptococcus Thermophilus (DSM 24731) Lactobacillus Acidophilus (DSM 24735), Lactobacilus Casei (DSM 24733), Lactobacillus Delbrueckii Subsp, Bulgaricus (DSM 24734), Lactobacillus Plantarum (DSM 24730). Appropriate overages added to compensate loss on storage.

Indications: For management of rotavirus diarrhoea in children.

Contra-indications: Hypersensitivity to the active substance or to any of the excipients listed in the formulation.

Warnings and precautions: Florimax Jr sachets are typically compatible with most medications. If taking antibiotics, it is recommended to take Florimax Jr at a different time to avoid potential interactions. Exercise caution when using Florimax Jr in patients with lactose intolerance or a milk allergy, and assess individual tolerance to ensure safety and effectiveness. Do not exceed the stated recommended daily dose.

Adverse effects: Mild bloating. If you encounter bloating, it is advisable to reduce your daily dosage.

Dosage of administration: 1-2 sachets a day with single or divided doses. Mix the contents of sachet in infant formula, cold milk, water, yogurt or juice, and consume immediately. Do not exceed the recommended daily dose.

(For detailed information please write to Zuventus Healthcare Limited, Plot Y2, CTS No: 358/A2, Near Nahur Railway station, Nahur (west) Mumbai 400078 or email to medico@zuventus.com)

Zuventus has always been at the forefront in bringing innovation and excellence in Healthcare.

As part of this commitment to the medical fraternity & patients, Zuventus introduced a novel concept-based molecule, Trelagliptin (Trelaglip), a Once-Weekly Oral DPP4i for the management of Type 2 Diabetes Mellitus (T2DM), designed to address existing challenges in glycemic control & patient compliance.

Trelaglip makes a difference to QoL with Compliance & Control, available in 3 SKUs (100 MG, 50 MG & 25 MG) 

• For the first time in India, Zuventus conducted a clinical trial comparing Trelagliptin 100 MG (once-weekly) vs. Vildagliptin 50 MG BID & got CDSCO approval.

Aim and background: To assess the efficacy and safety of Ibutilide infusion for cardioversion of atrial fibrillation (AF) or flutter (AFL) to sinus rhythm. Materials and methods: This open-label, multicenter phase IV study was conducted at six sites across India. The study enrolled 120 patients (108 with AF, 12 with AFL), each receiving up to two, 10-minute intravenous doses of 1.0 mg Ibutilide. The primary endpoints were the proportion of patients achieving cardioversion and the mean time taken to achieve cardioversion. Secondary endpoints included the proportion of patients maintaining sinus rhythm at 24 hours and the incidence of adverse events.

Results: The cardioversion rate at 4 hours post-Ibutilide infusion among 120 patients was 65.83% (n = 79), with an average conversion time of 35.12 ± 36.71 minutes. At 24 hours, 85 patients (70.8%) had successful cardioversion, with a mean time of 107.24 minutes. The majority of patients (71.76%) had achieved cardioversion within 30 minutes. Of the 85 patients who achieved successful conversion, 82 (68.3%) maintained sinus rhythm at 24 hours. A total of 66 patients (55%) achieved cardioversion with the first bolus whereas 19 (15.8%) needed a second bolus. Atrial fibrillation patients had a higher conversion rate (75%) compared to AFL patients (33%). A total of 10 adverse events were recorded in eight patients (6.67%), including nausea, headache, palpitations, and bradycardia. Three severe cardiac events, one case of ventricular tachycardia, and two of tachycardia necessitated discontinuation of Ibutilide. No fatalities or serious adverse events (SAE) were reported.

Conclusion: Ibutilide was found to be effective and well-tolerated for rapid restoration of sinus rhythm in patients with AF or AFL.

Clinical Trial Registry of India: CTRI/2018/01/011248.

Keywords: Atrial fibrillation, Atrial flutter, Cardioversion, Ibutilide

Zuventus Healthcare Limited, Mumbai was voted in a Nation wide Poll conducted by Network 7 Research as India’s Most Respected Pharmaceutical Company by Medical Professionals 2024 at the 16th Annual Pharma Leaders Healthcare Super Brand Awards 2024 on Friday at Hilton Mumbai International Airport. Padma Shri Dr Mukesh Batra, Founder Chairman Emeritus, Dr Batra’s Healthcare presented the prestigious Award Trophy & Certificate of Excellence in the presence of Dr Satya Brahma, Founder & Editor-In-Chief of Network 7 Media Group.